[{"from": "human", "value": "What can you tell me about this molecule? [C][C@@H1][C][=C][Branch1][#Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][C][=Branch1][C][=O][N][Branch2][Ring2][Ring1][C][C][=N][N][Branch2][Ring1][O][C][=Branch2][Ring1][Branch1][=C][Ring1][Branch1][C][=C][C][=Branch1][=Branch2][=C][Branch1][Branch1][N][=C][Ring1][=Branch1][N][O][Ring2][Ring1][=Branch2][C][#N][C][C]"}, {"from": "gpt", "value": "The molecule is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC."}]